Source comparison
Best Tesamorelin + Ipamorelin Blend for Visceral Fat: Protocol Comparison
Before committing to a specific peptide protocol, understanding how different stacks compare in mechanism, timeline, and outcome helps match the approach to your research goals. Tesamorelin monotherapy (2mg/day) GHRH receptor agonism → pulsatile GH release → l
This comparison does not assign a generated winner or score.
- Before committing to a specific peptide protocol, understanding how different stacks compare in mechanism, timeline, and outcome helps match the approach to your research goals.
- Tesamorelin monotherapy (2mg/day)
- GHRH receptor agonism → pulsatile GH release → lipolysis in VAT
- 8–12% (moderate)
- Low. Single daily injection, fasted or fed
- Researchers prioritizing simplicity and proven clinical data
- Effective but leaves GH pulse duration and amplitude on the table—works, but slower than dual-pathway stacks
- Ipamorelin monotherapy (300mcg/day pre-sleep)
- Ghrelin receptor agonism → amplified nocturnal GH pulse → extended lipolytic window
- 5–8% (modest)
- Low. Single evening injection, fasted state required
- Researchers testing GH secretagogue response without GHRH commitment
- Amplifies existing GH secretion but doesn't create new pulses—less effective in individuals with already-suppressed GH baseline
- Tesamorelin 2mg AM + Ipamorelin 300mcg PM (dual administration)
- Dual-pathway: GHRH + ghrelin receptor → sustained GH elevation across 4–6 hours twice daily
- 12–18% (high)
- Moderate. Two daily injections, timing-sensitive (fasted AM, pre-sleep PM)
- Researchers targeting maximum VAT reduction with evidence-backed dosing
- Gold standard for visceral fat protocols—synergistic receptor targeting produces 30–40% greater VAT loss than monotherapy at equivalent GH AUC
- CJC-1295 (no DAC) + Ipamorelin
- GHRH analogue with 6–8 day half-life + ghrelin agonist → sustained GH elevation without daily injections
- 10–15% (moderate-high)
- Low. 2–3 injections per week
- Researchers prioritizing injection frequency reduction over precise control
- Effective but less precise—longer half-life makes dose adjustment slower and increases risk of sustained GH elevation beyond therapeutic window